Develops an investigational biologic for retinal diseases, including age-related macular degeneration, for patients with retinal conditions.
10-K for FY2025, filed Mar 17, 2026We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal…View ↗
We are developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (“VEGF”) drug, specifically engineered to achieve…View ↗
We are currently conducting a Phase 1b/2 multiple ascending dose (“MAD”), dose-finding study evaluating four monthly loading injections of…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$11MView ↗
8-K, filed Jul 20, 2026
On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief…View ↗
8-K, filed Apr 10, 2026
On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the “Company”) of his decision to resign as the Chief Financial Officer…View ↗
From cell therapies to retinal medicine
The older report described off-the-shelf T-cell therapies for viral diseases, including candidates for transplant patients; the latest report centers on an investigational treatment for retinal diseases.
10-K for FY2022, filed Feb 15, 2023 10-K for FY2025, filed Mar 17, 2026We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent…View ↗
Competes with Roche, Novartis, Regeneron, AbbVie, Eli Lilly, Merck, Samsung Bioepis, Biogen, Coherus BioSciences, Formycon, Sandoz Group, Mylan Laboratories, Biocon Biologics, Amgen, Outlook Therapeutics, 4D Molecular Therapeutics, RegenexBio, Eyepoint Pharmaceuticals, Ocular Therapeutix, and Kodiak Sciences
10-K for FY2025, filed Mar 17, 2026In addition to the current standard of care treatments for patients with nAMD, numerous commercial and academic pre-clinical studies and…View ↗
Loading...